Determination of c-myc amplification and overexpression in breast cancer patients: Evaluation of its prognostic value against c-erbB-2, cathepsin D and clinicopathological characteristics using univariate and multivariate analysis

British Journal of Cancer

Volumn 81, Issue 8, 1999, Pages 1385-1391

  Scorilas, A ^a,b   Trangas, T ^a   Yotis, J ^a   Pateras, C ^a   Talieri, M ^a  

^a SAINT SAVVAS HOSPITAL   (Greece)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Breast cancer; C erbB 2; C myc; Cathepsin D; Early relapse; Locoregional recurrence; Overall survival; Relapse free survival

Indexed keywords

CATHEPSIN D; CYCLOPHOSPHAMIDE; FLUOROURACIL; HORMONE RECEPTOR; METHOTREXATE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; ONCOGENE C ERB; ONCOGENE C MYC; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS;

EID: 0032739089     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6693404     Document Type: Article

References (47)

1. Alarscon R, Rupnow B, Graeber T, Knox S and Giaccia A (1996) Modulation of c-myc activity and apoptosis in vivo. Cancer Res 56: 4315-4319
2. Alitalo K and Schwab M (1986) Oncogene amplification in tumour cells. Adv Cancer Res 47: 235-281
3. Allred DC, Harvey JM and Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11: 155-168
4. Ben-Yosef T, Yanuka O, Halle D and Benvenistry N (1998) Involvement of myc targets in c-myc and N-myc induced human tumours. Oncogene 17: 165-171
5. Berns EMJJ, Klijn JGM, van Puten WLJ, van Staveren IL, Portengen H and Foekens JA (1992a) c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. Cancer Res 52: 1107-1113
6. Berns EMJJ, Klijin JGM, van Staveren IL, Portengen H, Noordegraaf E, Foekens JA (1992b) Prevalence of amplification of the oncogenes c myc, HER2/neu, and int-2 in one thousand human breast tumours: Correlation with steroid receptors. Eur J Cancer 28: 697-700
7. Berns EM, Klijin JG, Smid M, van Staveren IL, Look MP, van Putten WI, and Foekens JA (1996) TP53 and MYC gene alterations independently predict poor prognosis in breast cancer patients. Genes Chromosomes Cancer 16: 170-179
8. Bland KI, Konstadoulakis MM, Vezeridis MP and Wanebo HJ (1995) Oncogene protein co-expression: value of IIa ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma. Ann Surg 221: 706-720
9. Chomezynski P and Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159
10. Dati C, Antoniotti S, Taverna D, Perroteau I and De Bortoli M (1990) Inhibition of c-erbB-2 ocogene expression by estrogens in human breast cancer cells. Oncogene 5: 1001-1006
11. Dubik D and Shiu RPC (1988) Transcriptional regulation of c-myc oncogene expression by oestrogen in hormone-responsive human breast cancer cells. J Biol Chem 263: 12705-12708
12. Escot C, Theillet C, Lidereau R, Spyratos F, Champerne MH, Gest J and Callahan R (1986) Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas. Proc Natl Acad Sci USA 83: 4834-4838
13. Feinberg A and Vogelstein B (1984) A technique for labelling DNA restriction fragments to a high specific activity. Anal Biochem 137: 66-67
14. Ferrandina G, Scambia G, Benedetti-Panici P, Mancuso S and Messori A (1997) Relationship between Cathepsin-D content and disease-free survival in node-negative breast cancer patients: a meta-analysis. Br J Cancer 76(5): 661-666
15. Foekens JA, Berns EMJJ, Look MP et al (1996) Prognostic factors in node-negative breast cancer. In: Hormone-Dependent Cancer, Pasqualini JR and Katzenellebogen BS (eds), pp. 217-253. Dekker: New York
16. Garcia I, Dietrich PY, Aapro M, Vauthier G, Vadas L and Engel F (1989) Genetic alteralion of c-myc, c-erbB-2 and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas. Cancer Res 49: 6675-6679
17. Gasparini G, Gozza F and Harris AL (1992) Evaluating the potential usefulness of new prognostic and predictive indicators in axillary node-negative breast patients. J Natl Cancer Inst 12: 1006-1014
18. Guerin M, Barrois M and Terrier M (1988) Overexpression of either c myc or c-erbB-2 (neu) proto-oncogene in human breast carcinomas: correlation with poor prognosis. Oncogene Res 3: 21-31
19. Kaplan EL and Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
20. Kreipe H, Feist H, Fischer L, Felgner J, Heidorn K, Mettler L and Parwaresch R (1993) Amplification of c-myc but not of c-erbB-2 is associated with high proliferative capacity in breast cancer. Cancer Res 53: 1956-1961
21. Lonn U, Lonn S, Nilsson B and Stenkvist B (1995) Prognostic value of erb-B2 and myc amplification in breast cancer imprints. Cancer 75: 2681-2687
22. Losch A, Templer C, Kohlberger P, Joura EA, Denk M, Zajic B, Breitenecker G and Kainz C (1998). Prognostic value of cathepsin-D expression and association with histomorphological subtypes in breast canter. Br J Cancer 78: 205-209
23. Maniatis T, Fritsch EF and Sambrock J (1982) Molicular Cloning: a Laboratory Manual. Cold Spring Harbour Press: New York
24. McGuire WL (1991) Breast cancer prognostic factors: evaluation guidelines. J Natl Cancer Inst 83: 154-155
25. Miyada CG and Wallace RB (1987) Oligonucleotide hybridization techniques Methods in enzymol. 154: 94-107
26. Nass SJ and Dickson RB (1997) Defining a role for c-myc in breast tumorigenesis, Breast Cancer Res Treat 44: 1-22
27. Osborne CK (1992) Prognostic factors for breast cancer: have they met their promise? J Clin Oncol 10: 679-682
28. Pavelic ZP, Pavelic L, Lower EE, Gapany S, Barker EA and Preisler HD (1992) c-myc, c-erbB-2 and Ki-67 expression in normal in breast tissue and in invasive and non invasive breast carcinoma. Cancer Res 52: 2597-2602
29. Pertsehuk LP, Feldman JG, Kim DS, Nayeri K, Eisenberg KB, Carte AC. Thelmo WT, Rhong ZT, Benn P and Grossman A (1993) Steroid hormone receptor immunobistochomistry and amplification of c-myc protooncogene. Relationship to disease-free survival in breast cancer, Cancer 71: 162-171
30. Pietilainen T, Lipponen P, Aaltomaa S, Eskelinen M, Kosma VM and Syrjanen K (1995) Expression of c-myc proteins in breast cancer as related to established prognostic factors and survival. Anticancer Res 15: 959-964
31. Prall OW, Rogan EM and Sutherland RL (1998) Estrogen regulation of cell cycle progression in breast cancer cells. J Steroid Biochem Mol Biol: 65: 169-174
32. Read LD, Keith D Jr, Slamon DJ and Katzenellebogen BS (1990) Hormone modulation of HER2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. Cancer Res 50: 3947-3951
33. Rochefort H (1992) Biological and clinical significance of cathepsin-D in breast cancer. Acta Oncol 31: 125-130
34. Roux-Dosseto M, Romain S, Dussault N, Desideri C, Piana L, Bonnier P et al (1992) c-myc gene amplification in selected node-negative breast cancer patients correlates with high rate of early relapse. Eur J Cancer 28A: 1600-1604
35. Santos GF, Scott GK, Lee WMF, Liu E, and Benz C (1988) Estrogen-induced posttranscriptional modulation of c-myc proto-oncogene expression in human breast cancer cells J Biol Chem 263: 9565-9568
36. Scorilas A, Yotis J, Gouriotis D, Keramopoulos A, Ampela K, Trangas T and Talieri M (1993) Cathepsin-D and c-erbB-2 have an additive prognostic value for breast cancer patients. Anticancer Res 13: 1895-1900
37. Scorilas A, Yotis J, Stravolernos K, Gouriotis D, Keramopoulos A, Ampela K, Talieri M and Trangas T (1995) c-erbB-2 overexpression may be used as an independent prognostic factor for breast cancer patients. Anticancer Res 15: 1543-1548
38. Scorilas A, Yotis J, Pateras Ch, Trangas T and Talieri M (1999) Predictive value of c erbB-2 and Cathepsin-D for Greek breast cancer patients using univariate and multivariate analysis. Clinical Cancer Res 5: 815-821
39. Sistonen L, Koskinen PJ, Lehvaslaiho H, Lehtola L, Bravo R and Alitalo K (1990) Down regulation of the early genomic growth factor response in neu oncogene transformed cells. Oncogene 5: 815-821
40. Sjogren S, Inganas M, Lindgren A, Holmberg L and Bergh J (1998) Prognostic and predictive value of c erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 16: 462-469
41. Spyratos F, Maudelonde T, Brouillet JP, Brunet M, De-Fene A, Andrieu C, Harene K, Desplaces A, Rouesse J and Rochefort H (1989) Cathepsin-D: an independent prognostic factor for metastasis of breast cancer. Lancet ii: 1115-1118
42. Suen TC and Hung MC (1991) c-myc reverses neu-induced transformed morphology by transcriptional repression. Mol Cell Biol 11: 354-362
43. Thomas PS (1980) Hybridization of denatured RNA and small DNA fragments transferred to a high specific activity. Proc Natl Acad Sci USA 77: 5201-5205
44. Thor AD and Yandell DW (1996) Molecular pathology of breast carcinoma. In: Diseases of the Breast, Harris JR, Lippman ME, Morrow M and Hellman S (eds), pp. 221-235. Lippincott-Raven: Philadelphia
45. Tormod B and Egil A (1985) Selecting factors: a comparison of discriminant analysis logistic regression and Cox's regression model using data from the Tromso heart study. Stat Med 4: 413-423
46. Van der Burg B, van Selm-Miltenburg AJP, de Last SW and van Zuolen EJJ (1989) Direct effects of estrogen on c-fos and c-myc protooncogene expression and cellular proliferation in human breast cancer cells. Mol Cell Endocrinol 64: 223-228
47. Watson PH, Singh R and Hole AK (1996) Influence of c-myc on the progression of human breast cancer. Curr Top Microbiol Immunol 213: 267-283